FluMist, also known as live-attenuated influenza vaccine (LAIV), has been recommended for healthy children as young as 2 years of age by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. The expanded recommendation gives physicians the choice of using LAIV or inactivated trivalent influenza vaccine (TIV) in healthy children 2-18 years of age for whom influenza immunization is indicated.

Children under 5 years of age with recurrent wheezing or a wheezing episode in the past 12 months should not receive FluMist due to the potential for increased wheezing post vaccination.

LAIV and TIV (see table) contain the same strains of influenza A (i.e.,subtypes H1N1 and H3N2) and influenza B, which are selected annually based on the influenza viruses expected to circulate during the upcoming season. Both influenza vaccines have been demonstrated to be effective in children and adults. LAIV was licensed by the Food and Drug...

You do not currently have access to this content.